<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">23049</article-id><article-id pub-id-type="doi">10.7554/eLife.23049</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>TAPBPR bridges UDP-glucose:glycoprotein glucosyltransferase 1 onto MHC class I to provide quality control in the antigen presentation pathway</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-37224"><name><surname>Neerincx</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-37221"><name><surname>Hermann</surname><given-names>Clemens</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-45164"><name><surname>Antrobus</surname><given-names>Robin</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-37222"><name><surname>van Hateren</surname><given-names>Andy</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3915-0239</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-75172"><name><surname>Cao</surname><given-names>Huan</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-37223"><name><surname>Trautwein</surname><given-names>Nico</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32347"><name><surname>Stevanović</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-37226"><name><surname>Elliott</surname><given-names>Tim</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15515"><name><surname>Deane</surname><given-names>Janet E</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4863-0330</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-36640"><name><surname>Boyle</surname><given-names>Louise H</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3105-6555</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Pathology</institution>, <institution>University of Cambridge</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff2"><institution content-type="dept">Department of Integrative Biomedical Sciences, Division of Chemical and Systems Biology, Institute for Infectious Disease and Molecular Medicine</institution>, <institution>University of Cape Town</institution>, <addr-line><named-content content-type="city">Cape Town</named-content></addr-line>, <country>South Africa</country></aff><aff id="aff3"><institution content-type="dept">Cambridge Institute for Medical Research</institution>, <institution>University of Cambridge</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff4"><institution content-type="dept">Faculty of Medicine and Institute for Life Science</institution>, <institution>University of Southampton</institution>, <addr-line><named-content content-type="city">Southampton</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff5"><institution content-type="dept">Division of Applied Medicine, Institute of Medical Sciences</institution>, <institution>University of Aberdeen</institution>, <addr-line><named-content content-type="city">Aberdeen</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff6"><institution content-type="dept">Department of Immunology</institution>, <institution>Eberhard Karls University Tübingen</institution>, <addr-line><named-content content-type="city">Tübingen</named-content></addr-line>, <country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-62727"><name><surname>Margulies</surname><given-names>David H</given-names></name><role>Reviewing editor</role><aff><institution>National Institutes of Health</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>lhb22@cam.ac.uk</email> (LB);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>20</day><month>04</month><year>2017</year></pub-date><volume>6</volume><elocation-id>e23049</elocation-id><history><date date-type="received"><day>07</day><month>11</month><year>2016</year></date><date date-type="accepted"><day>14</day><month>04</month><year>2017</year></date></history><permissions><copyright-statement>© 2017, Neerincx et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Neerincx et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-23049-v1.pdf"/><abstract><p>Recently we revealed that TAPBPR is a peptide exchange catalyst important for optimal peptide selection by MHC class I molecules. Here we asked if any other co-factors associate with TAPBPR which would explain its effect on peptide selection. We identify an interaction between TAPBPR and UDP-glucose:glycoprotein glucosyltransferase 1 (UGT1), a folding sensor in the calnexin/calreticulin quality control cycle known to regenerate the Glc<sub>1</sub>Man9GlcNAc<sub>2</sub> moiety on glycoproteins. Our results suggest the formation of a multimeric complex, dependent on a conserved cysteine at position 94 in TAPBPR, in which TAPBPR promotes the association of UGT1 with peptide-receptive class I molecules. We reveal that the interaction between TAPBPR and UGT1 facilities the reglucosylation of the glycan on class I, promoting their recognition by calreticulin. Our results suggest that in addition to being a peptide-editor, TAPBPR improves peptide optimisation by promoting peptide-receptive MHC class I molecules to associate with the peptide-loading complex.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome</institution></institution-wrap></funding-source><award-id>Senior Research Fellowship 104647</award-id><principal-award-recipient><name><surname>Neerincx</surname><given-names>Andreas</given-names></name><name><surname>Boyle</surname><given-names>Louise H</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000288</institution-id><institution>Royal Society</institution></institution-wrap></funding-source><award-id>University Research Fellowship,UF100371</award-id><principal-award-recipient><name><surname>Deane</surname><given-names>Janet E</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>Programme Grant,C7056A</award-id><principal-award-recipient><name><surname>van Hateren</surname><given-names>Andy</given-names></name><name><surname>Elliott</surname><given-names>Tim</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>SFB 685</award-id><principal-award-recipient><name><surname>Trautwein</surname><given-names>Nico</given-names></name><name><surname>Stevanović</surname><given-names>Stefan</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome</institution></institution-wrap></funding-source><award-id>PhD studentship,089563</award-id><principal-award-recipient><name><surname>Hermann</surname><given-names>Clemens</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome</institution></institution-wrap></funding-source><award-id>Strategic Award 100140</award-id><principal-award-recipient><name><surname>Antrobus</surname><given-names>Robin</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome</institution></institution-wrap></funding-source><award-id>programme grant,WT094847MA</award-id><principal-award-recipient><name><surname>Cao</surname><given-names>Huan</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="datasets"><title>Major datasets</title><p/><p>The following datasets were generated:</p><p><related-object content-type="generated-dataset" id="dataro1" source-id="doi:10.5061/dryad.8fh3g" source-id-type="uri"><collab>Neerincx A</collab>, <collab>Hermann C</collab>, <collab>Antrobus R</collab>, <collab>Andy vH</collab>, <collab>Huan C</collab>, <collab>Trautwein N</collab>, <collab>StevanoviÄ‡ S</collab>, <collab>Elliott T</collab>, <collab>Deane JE</collab>, <collab>Boyle LH</collab>, <year>2016</year><x>,</x> <source>Data from: TAPBPR bridges UDP-glucose:glycoprotein glucosyltransferase 1 onto MHC class I to provide quality control</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="doi:10.5061/dryad.8fh3g">doi:10.5061/dryad.8fh3g</ext-link><x>,</x> <comment>Available at Dryad Digital Repository under a CC0 Public Domain Dedication</comment></related-object></p></sec><supplementary-material><ext-link xlink:href="elife-23049-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>